New research indicates that patients who discontinue new GLP-1 drugs like Wegovy and Mounjaro can put back on reduced body mass much more quickly than those who end conventional lifestyle regimens.
Findings released in a prominent health publication demonstrates that while overweight individuals often shed a large proportion of their total mass while undergoing treatment, the weight comes back at an average rate of 0.8 kg per month once they quit.
"People buying these drugs need to be aware of the potential of rapid rebound weight gain when the therapy is stopped," stated expert Dr. Susan Jebb.
This pace of recovery implies a reversion to pre-treatment mass within about one and a half years.
Weighing Therapies
The analysis, which reviewed dozens of studies involving thousands of patients, contrasted the effects of GLP-1 agonists with conventional dieting.
The team emphasize that people who shed pounds through lifestyle changes alone generally see a less rapid creep back—approximately 0.1 kg a month—after stopping.
Understanding the Rapid Rebound
Nutrition scientists suggest the mode of action of the injections is key to understanding the amplified rebound.
GLP-1 drugs copy a body's own chemical called GLP-1, which helps regulate appetite.
"Sustained high doses of the hormone concentrations far above than normal could lead to the body to produce less of its endogenous GLP-1, and may also reduce responsiveness to its effects," explained Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this medication results in hunger is uncontrolled, making binge eating much more probable."
A Chronic Issue?
The NHS suggest the injections for individuals with weight-linked health risks, alongside recommended diet and exercise modifications.
Professionals argue that, considering the high risk of relapse, the therapy should be considered life-long.
This perspective is reinforced by pharmaceutical companies, who say that the results "emphasize the persistent character of obesity," akin to managing diseases like diabetes.
User Accounts
Individuals who have discontinued the jabs explain a powerful resurgence of appetite.
"It was like a switch flipping and you're instantly starving," recalled one woman.
This challenge is exacerbated if individuals have not established permanent dietary or behavioural modifications during treatment.
Growing Interest
Figures suggest that millions of adults in the UK have used weight-loss jabs in the past year, with demand continuing to grow.
- Use is higher among females than men.
- The middle-aged age group shows the greatest usage rates.
- A large proportion access the medications through private healthcare rather than public health services.
In conclusion, researchers caution that while GLP-1 drugs are potent tools for shedding pounds, they are not a standalone fix and maintained weight loss likely depends on combined lifestyle changes.
